Pharmacology and Analytical Facility - HPLC and Mass Spectrometry Facility This facility provides access to sophisticated HPLC, ultra high performance liquid chromatographic and mass spectrometry instruments. In this facility, analytical assay methodologies can be developed and validated using UPLC/HPLC equipment with a broad array of quantitative detection systems (e.g. UV, photodiode array, fluorescence, radiometric, light scattering, electrochemical). Current mass spectrometry instruments include a simple single quad LC/MS instrument for use in molecular weight determinations as well as more complex tandem mass spectrometers (7 total), including a time-of-flight instrument for more intricate drug metabolism studies and experiments requiring accurate mass weight measurements. In addition, a GC/MS instrument is available for separation and quantitation of volatile compounds. Recently added were automated solid phase and liquid extraction platforms capable of isolating multiple analytes of interest (drugs, macromolecules, and protein drug targets) from complex biomatrices (blood, plasma, normal organ tissues, and tumors). These extraction systems have improved both extraction efficiency and throughput in analytical sample preparation. The laboratory has supported experiments in chemical synthesis, drug library screening, medicinal chemistry, drug discovery and development, drug metabolism, drug target identification, drug metabolism, drug tissue biodistribution, systemic pharmacokinetics, drug production solubility and stability, formulation, and tumor biochemistry. The HPLC/Mass Spectrometry Facility sampled analysis increased over 340% since 1999 and is now analyzing more than 33,000 samples per year serving over 52 faculty members who are members of 21 CCSG Programs;90% of the users have peer-reviewed funding. The current source of funding is 48.4% CCSG, and 51.6% user fees. This state of the art facility is located at a newly renovated El Rio campus located approximately 1 mile from the main campus. This location is a 7250 sq. ft. facility that houses 4 faculty members and 21 support staff as well as 25 full UPLC/HPLC systems. In addition to the advanced analytical facility the combined program faculty have in excess of 60 years of experience in analytical chemistry, analytical method development and validation, isolation technologies, pharmacology, drug metabolism, and pharmacokinetic/pharmacodynamics. They act as an invaluable resource in experimental design, development and implementation to the user faculty who often lack the specific training to conduct experiments requiring quantitative analytical chemistry and pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-37
Application #
8379459
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$439,088
Indirect Cost
$154,461
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :
Cassani, Lisa S; Raju, Gottumukkala S (2016) Techniques for management of bleeding associated with colonic endoscopic mucosal resection. Gastrointest Endosc 83:469-70
Zargar, Homayoun; Atwell, Thomas D; Cadeddu, Jeffrey A et al. (2016) Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. Eur Urol 69:116-28
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2016) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res :
Jinesh, Goodwin G; Kamat, Ashish M (2016) Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. Cell Death Discov 2:
Maiti, Abhishek; Cortes, Jorge E; Brown, Yolanda D et al. (2016) Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk Lymphoma :1-4
Visone, R; Pallante, P; Vecchione, A et al. (2016) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 35:5214
Zhou, Fuling; Li, Ming; Wei, Yongchang et al. (2016) Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells. Oncotarget :
Gamaletsou, Maria N; Rammaert, Blandine; Bueno, Marimelle A et al. (2016) Candida Arthritis: Analysis of 112 Pediatric and Adult Cases. Open Forum Infect Dis 3:ofv207
Parra, Edwin R; Behrens, Carmen; Rodriguez-Canales, Jaime et al. (2016) Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res :

Showing the most recent 10 out of 9121 publications